Entero signs Letter of Intent to license and commercialize remote patient and machine vision ...
Entero Therapeutics to exclusively license Data Vault's QOLPOM and FotoDigm software for GI clinical trials, with plans to secure up to $3 million in strategic investment. The deal aims to improve clinical trial compliance and outcomes, leveraging Data Vault's technology for Entero's phase 3 latiglutenase trial for celiac disease.
Reference News
Entero signs Letter of Intent to license and commercialize remote patient and machine vision ...
Entero Therapeutics to exclusively license Data Vault's QOLPOM and FotoDigm software for GI clinical trials, with plans to secure up to $3 million in strategic investment. The deal aims to improve clinical trial compliance and outcomes, leveraging Data Vault's technology for Entero's phase 3 latiglutenase trial for celiac disease.